As evidence-based guidelines increasingly define standards of care, the accurate reporting of patterns of treatment becomes critical to determine if appropriate care has been provided. We explore the level of agreement between claims and record abstraction for treatment regimens for prostate cancer.
METHODS
The Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries (NPCR) patterns of care for breast and prostate cancer study (POCBP) was the source of data for this study. Data related to the diagnosis and treatment of breast and prostate cancers diagnosed in 2004 were reabstracted from hospitals, radiation facilities, and oncologists' offices in 7 states (California, Georgia, Kentucky, Louisiana, Minnesota, North Carolina, and Wisconsin), including 9017 randomly selected cases of invasive prostate cancer (C61.9). Minorities and Appalachian residents were over sampled. Cases diagnosed at Veterans Affairs hospitals and through autopsies or deaths certificates were excluded. Institutional Review Board approval was secured from 5 of the 7 states to send unique patient identifiers to the Centers for Medicare and Medicaid Services to link POCBP data with Medicare claims. Medicare is the primary insurer for 97% of the US population aged 65 years and older, covering inpatient hospital care (part A) and outpatient care and physician services (part B). There were 6862 men with prostate cancer from the 5 participating states. Records for these men were linked to claims data to capture treatment in the 12 months after diagnosis. We excluded 2968 patients because they were under 65 years of age. Another 1129 patients were excluded because they had incomplete Medicare coverage, managed care enrollment, or lack of Medicare claims. The final sample was 2765 patients.
TREATMENT ASSESSMENT MEDICAL RECORDS
The overall goal of the POCBP study was to ascertain whether or not the patient had received guideline-concordant care based on National Comprehensive Cancer Network guidelines for prostate cancer 17 in their year of diagnosis. To obtain complete treatment data to assess quality of care, registries reviewed not only hospital medical records but also outpatient records when there was no adequate information to determine guideline-concordant care.
Definitions of Treatment
We used the standard North American Association of Central Cancer Registries data collection rules (http://seer. cancer.gov/tools/codingmanuals/historical.html) to gather information on first course of treatment and defined it as the therapy regimen that is given or planned. First course of treatment could extend up to 1 year or more after cancer diagnosis. We categorized surgery as: (1) prostatectomy (simple, subtotal, segmental, or radical); (2) cryosurgery; (3) hyperthermia, laser surgery, radiofrequency ablation, or microwave. We differentiated RT into: (1) external beam (including 3D combination RT); (2) brachytherapy; and (3) combination of external beam and brachytherapy, seed, or radiotherapy. Hormonal therapy was based on receipt of luteinizing hormone-releasing hormone (LHRH) agonists including goserelin acetate, leuprolide, and leuproliden implants.
Other Covariates
Covariates in the multivariate models were AJCC stage (stages I, II, III, or IV), 18 comorbidity score from the ACE-27 comorbidity index (none, mild, moderate, or severe), 19 age (65-74 vs. 75+ y), urban/rural location, race/ethnicity (White, non-Hispanic; Black, non-Hispanic; American Indian/Alaska Native (AI/AN), non-Hispanic, Asian/Pacific Islander (API), non-Hispanic, Hispanic), source of payment (Medicaid, private insurance, or none vs. Medicare or other public payer), source of medical records (hospital chart only not requiring physician verification, no verification of physician offices, or unified chart vs. 1 or more physician offices), and cancer registry.
TREATMENT ASSESSMENT CLAIMS
We derived treatment information from all available Medicare claims files (hospital, outpatient, physician, hospice, home health, durable medical equipment, and skilled nursing) during a 1-year time window after cancer diagnosis. Service codes categorize services by type. We only used claims from the physician file with a service code of medical, surgical, or consultation, and thereby assume that such claims were more likely to be recorded or "directed" by physicians. Claims with other service codes, for example, radiology and laboratory, were excluded. Treatments were classified similar to their medical record counterparts but on the basis of International Classification of Diseases, 20 Current Procedure Terminology, 21 or Healthcare Common Procedure Coding System codes (Appendix 1).
STATISTICAL ANALYSIS
We reported patient, payer, and sociodemographic characteristics of our included sample and those patients who were excluded from the analysis, and tested for significant differences. We assessed agreement between the Medicare claims and POCBP-abstracted medical records for surgery, radiation, and LHRH hormonal therapy, and calculated the sensitivity of the Medicare claims data using the POCBP medical records as the "gold standard." We assessed reliability by calculating the k statistic for each treatment component, and various combinations of these components, and interpreted the k statistics according to the following 22 : excellent (0.81-1.00), substantial (0.61-0.80), moderate (0.41-0.60), fair (0.21-0.40), slight (0.00-0.20), and <0.00 (poor). We also assessed sensitivity of the claims data when using different sources of Medicare claims (eg, inpatient only and inpatient plus physician.) Finally, we estimated 3 multivariate logistic regressions for the 3 treatment outcomes (surgery, radiation, and LHRH hormonal therapy) to identify predictors of agreement between claims and records for surgery, radiation, or LHRH agonist therapy. SAS version 9.2 and 9.3 was used in all analyses.
RESULTS
Patient characteristics of men aged 65+ whose records were linked to Medicare claims and those who were not able to be linked for various reasons are shown in Table 1 . There were statistically significant differences between the study sample and those not included in the study with respect to age, stage, payer, urban/rural location, registry, and race/ ethnicity. In particular, cases not included in the study were more likely Hispanic and API, private pay or uninsured, from urban areas, and residents of 1 urban registry from a state with high proportion of HMO patients (P < 0.01 for race, payer, urban/rural location, and registry).
When Medicare claims were compared with records abstraction (Table 2) , the k statistics for surgery and RT were high (0.92 and 0.92, respectively) as were the sensitivities of claims using records as the gold standard for all of the surgical or RT options overall (96.8% and 96.2%, respectively). For detecting treatment with LHRH agonists, overall sensitivity of claims was high (95.3%) and k was 0.71. As LHRH agonists are administered in the outpatient setting, it was of interest to find that there were 335 cases (or nearly 27%) where claims indicated use of LHRH agonists but medical records did not, compared with 47 (5%) for which use was only indicated in the medical records data. When the analysis was stratified by state (unreported) for LHRH, the percentage of claims not documented by records ranged from 21.6% to 40.8% across the 5 states, and the percentage of records not represented by claims ranged from 0% to 11.8%. The sensitivities of individual local treatment modalities were nearly as high as the overall treatment categories with the exception of the category of the less commonly used treatments of laser ablation, hyperthermia, radiofrequency, or microwave treatments.
The most common single and combination treatment options were external beam radiation with LHRH agonists, radical prostatectomy only, and LHRH agonists only ( Table 3 ). The highest sensitivities are reported for cryosurgery with LHRH agonists (96.6%) and radical prostatectomy alone (91.9%). Relatively low sensitivities were found for some regimens, including external beam radiation only (56.6%), combination RT alone (77.2%), brachytherapy with hormonal therapy (73.7%), and the no treatment option (64.7%).
The effect of using different sources of claims data (Table 4) show that Medicare hospital claims only were unable to identify hyper/laser surgery, any kind of RT, and LHRH agonists. For surgery, sensitivity for radical prostatectomy was high with hospital files alone and not substantially improved with additional files. For cryosurgery, sensitivity improved after adding physician files to hospital files. Sensitivity for external beam radiation and combination RT improved substantially when outpatient files were added to hospital and physician files, although additional files did not improve sensitivity for brachytherapy.
We conducted 3 separate multivariate logistic regression models to predict concordance between claims and records for (1) any surgery, (2) any radiation, and (3) hormonal therapy ( Table 5 ). All regression models included covariates for state registries, comorbidity burden, age, location (urban, rural, and mix), race/ethnicity, source of payment, and abstraction method. Those with mild or severe comorbidity (vs. none) or stage 1 prostate cancer (vs. 4) were less likely to have concordance for surgery [odds ratio (OR) = 0.677, 0.400, and 0.212, respectively]. Younger men were much more likely to have concordance (OR = 2.245) and those whose records were abstracted from hospital charts only had half the odds of concordance for surgery (OR = 0.547). The odds of agreement for RT from both sources of data were lower for patients with stage 2 (vs. 4) disease (OR = 0.270). The odds of concordance for hormonal therapy was higher for those with stage 1 or 2 (vs. 4) but lower for those with a source of payment of Medicaid (vs. Medicare and other public insurances) (OR = 4.336, 2.627, and 0.653, respectively).
DISCUSSION
We compared Medicare claims to medical record review as sources for information on treatment regimens for prostate cancer. The results showed that claims are a sensitive source of information even for multicomponent treatment strategies including specific types of surgery or radiation and hormonal therapy. Findings regarding the sensitivity of Medicare claims using records as the gold Although there is some discordance between medical claims compared with chart review or tumor registry data with respect to type of surgery, receipt of chemotherapy, and radiation, previous studies have found agreement to be relatively high between the 2 sources for single therapies. This has been demonstrated for prostate, breast, and other cancers. [9] [10] [11] [12] [13] For example, Virnig et al 13 reported k statistics of 0.84-0.89 for prostate cancer treatment when comparing Medicare claims to Surveillance, Epidemiology, and End Results (SEER) data, with slightly higher rates of agreement for radical surgery versus resection or no surgery/biopsy. Virnig et al 13 showed that radiotherapy for prostate cancer also seems to be consistently reported in both claims and medical records. A comparison of any radiation treatment on Medicare claims to radiation treatment reported by the SEER program found a level of agreement of 93.1% for prostate cancer with a k statistic of 0.85.
We found the sensitivity of Medicare claims to records for hormonal therapy using LHRH agonists to be 95.3%, and that Medicare claims identified about one-third more patients with this therapy than record review (1247 vs. 959 patients). Kuo et al 23 studied GnRH agonists use in men with SEER-Medicare data. They found that 8.9% of incident GnRH users had no prostate cancer diagnosis in SEER data, and that GnRH users without a tumor registry diagnosis were more likely to be older, black, and have comorbidities; factors that are probably typical of patients with incomplete diagnostic evaluations for cancer. 16, 24, 25 Our finding that claims data are an important source of information on hormonal therapy complements the work of Kou and suggests that these data are useful as both diagnosis and treatment indicators.
Use of additional Medicare files compared with hospital claims alone improved the comparability of claims A modest level of agreement was found for some specific treatment regimens. For example, nearly 27% of LHRH therapy recognized in claims was not recognized by record review. The scope and method of data collection of the POCBP study may be a factor. Although medical record abstraction is considered by most the "gold standard" of first course of treatment, such abstraction often focuses only on the hospital record. 22 By contrast, the POCBP abstractors also reviewed outpatient data for most cases. This notwithstanding, the claims data indicate that there were components of care that may have been missed by chart reviews. That there are claims undocumented in the medical record is therefore not surprising given that there was variability in the extent to which the registries pursued outpatient records from radiation facilities and oncologist offices. As LHRH is commonly administered in an outpatient setting, these therapies may have been missed in the reabstraction from registries than were less aggressive in the pursuit of outpatient records. In addition, the medical record abstraction was directed toward first course of treatment regimens, whereas Medicare claims were reviewed within a predefined time window of 1 year. Therefore as we could not discern the endpoint for first course of therapy in claims, Medicare claims could not distinguish between adjuvant/curative RT and palliative RT. If first course of treatment exceeded 1 year, the treatment would be recognized by record review but not by claims. This may lead to an underestimate of agreement and sensitivity of claims to records; however, this did not seem to be reflected in our data as sensitivity was uniformly high and when there was disagreement between the 2 sources, it was more likely that the treatment was reported in the Medicare data than in the medical records. We also found that no treatment was much more likely to be suggested by medical records and that hormonal therapy and radiation were much more likely to be suggested by claims. At least some of this discordance could reflect active surveillance followed by a second course of treatment or palliative care after progression. In such cases, medical records would have no treatment recorded as only the first course of treatment is abstracted, but claims would pick up subsequent courses of treatment and palliative care occurring in the first year. The multivariate analyses to identify predictors of concordance was only somewhat elucidating. It is unclear why comorbidity burden or earlier stage of disease would lead to less agreement, except to the extent that such patients may be more likely to be treated in an outpatient setting only. This would be supported by the finding that reabstraction from hospital charts only had half the odds of concordance compared with patients whose records abstraction included at least 1 physician office.
We are aware of both strengths and weaknesses of our study. Strengths include the large sample size and geographic diversity, including data from 5 different states. Moreover, the POCBP study used a thorough method of chart review, 26 with reabstraction of hospital records and contact with doctors' offices. The follow-up was active and more focused for treatment information than registries funded by the CDC's NPCR. Thus inclusion of treatment information from the medical record review in this study should be more complete than that obtained routinely by both SEER and NPCR tumor registries.
Limitations include the timing of the POCBP abstracting (nearly 5 y after diagnosis when some records may have been no longer available), and the inability to control for incongruities between the initial course of treatment time window for records and the 1-year time frame for Medicare claims. Limitations associated with the claims data include the purpose of claims being primarily for reimbursement, 2 the bundling of some procedures into office visits, 3 providers failing to bill for some procedures, 4,5 the underreporting of chronic disease, other underlying conditions, or procedures that do not result in additional reimbursement, 6, 7 and coding errors. 8, [27] [28] [29] [30] Finally, the study is limited to men 65 years and older, those with complete Medicare coverage, and no managed care involvement.
In conclusion, claims are a readily available, inexpensive, and convenient source of data for epidemiologic research, and we have shown that, for prostate cancer, they provide greater coverage of hormonal therapy, which is often delivered in the outpatient setting. Medical record review is considerably more expensive and logistically difficult. Although it has the reputation of being a more sensitive metric for identifying treatment patterns, it is not without flaws. 31 It would seem prudent at this juncture to establish the extent to which claims are an acceptable, accurate, and sensitive source of specific cancer treatment regimens. As Medicare claims are a highly sensitive source of information on surgery, radiation, and hormonal therapy for prostate cancer compared with medical records, we suggest using claims as a supplement to registry data, the utility of which has been demonstrated by others 16 or when collection of complete treatment data through medical record review is unfeasible. 
